Immuneering Stock Forum

Immuneering's Breakthrough: Positive Phase 1 Trial Results for IMM-1-104 in RAS-Mutant Solid Tumors.
In a significant development in the fight against cancer, Immuneering Corporation (Nasdaq: IMRX) recently announced positive topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in patients with RAS-mutant solid tumors. This news is especially pertinent for those affected by RAS-mut...

Dr. Schall's appointment to Immuneering's board is viewed positively due to his vast biotech industry experience. His expertise could be crucial as Immuneering advances its universal-RAS/RAF cancer medicines pipeline.